Griseofulvin Treatment Guidelines for Fungal Infections

Dosing and Administration

• For a 14-year-old patient with fungal infections of the skin, hair, and nails, the British Journal of Dermatology recommends griseofulvin at a dose of 15-20 mg/kg/day for 6-8 weeks for tinea capitis, and 10 mg/kg/day for 6-9 months for fingernail infections or 12-18 months for toenail infections 1, 2, 3
• For patients with tinea capitis, the dosing guidelines are as follows: 15-20 mg/kg/day in single or divided doses for 6-8 weeks for patients less than 50 kg 1, 2
• For patients with tinea capitis, the dosing guidelines are as follows: 1 g/day in single or divided doses for 6-8 weeks for patients greater than 50 kg 4
• Higher doses up to 25 mg/kg/day may be required for resistant cases or prolonged treatment periods of tinea capitis 1
• Griseofulvin is particularly effective against Microsporum species (88.5% response rate) compared to Trichophyton species (67.9%) in the treatment of tinea capitis 1
• For children aged 1 month and above with onychomycosis, the recommended dose is 10 mg/kg/day (maximum 500 mg) 5
• The treatment duration for onychomycosis is 6-9 months for fingernail infections and 12-18 months for toenail infections 3, 5
• The British Journal of Dermatology suggests that while griseofulvin is licensed for children with onychomycosis, newer antifungals may be more effective for nail infections 6
• To increase absorption and improve bioavailability, griseofulvin should be taken with fatty food 1, 3
• Griseofulvin is available in several forms, including micronized, ultramicronized, and suspension 1

Efficacy and Safety

• Griseofulvin remains the only licensed product for treating tinea capitis in children in many countries, according to the British Journal of Dermatology 1, 4
• For tinea capitis caused by Trichophyton species, higher doses for longer periods (12-18 weeks) may be required 1
• The mycological cure rates for onychomycosis are only 30-40% for toenail infections 7
• Studies comparing griseofulvin with newer antifungals have demonstrated lower cure rates for griseofulvin in nail infections 7
• Common side effects of griseofulvin include gastrointestinal disturbances 1, 5, headaches 5, and skin rashes in less than 8% of patients 1
• Griseofulvin is contraindicated in patients with lupus erythematosus, porphyria, and severe liver disease 1, 5
• The plasma concentration of griseofulvin is decreased by rifampicin and increased by cimetidine 1

Treatment Monitoring and Considerations

• The endpoint of treatment should be mycological rather than clinical cure, as recommended by the British Journal of Dermatology 4
• Repeat mycology sampling is recommended until mycological clearance is achieved 4
• For resistant cases, consider lack of compliance, suboptimal absorption, relative insensitivity of the organism, and reinfection 4
• For tinea capitis, topical therapy alone is not recommended; oral therapy is generally indicated, according to the British Journal of Dermatology 4
• The choice of systemic therapy should be directed by the causative dermatophyte species 4
• For nail infections in children, griseofulvin is considered as second-line if itraconazole and terbinafine are contraindicated or not tolerated 5